508 related articles for article (PubMed ID: 34021390)
21. Whole Body 3.0 T Magnetic Resonance Imaging in Lymphomas: Comparison of Different Sequence Combinations for Staging Hodgkin's and Diffuse Large B Cell Lymphomas.
Latifoltojar A; Duncan MKJ; Klusmann M; Sidhu H; Bainbridge A; Neriman D; Fraioli F; Lambert J; Ardeshna KM; Punwani S
J Pers Med; 2020 Dec; 10(4):. PubMed ID: 33339372
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT.
Herrmann K; Queiroz M; Huellner MW; de Galiza Barbosa F; Buck A; Schaefer N; Stolzman P; Veit-Haibach P
BMC Cancer; 2015 Dec; 15():1002. PubMed ID: 26699124
[TBL] [Abstract][Full Text] [Related]
23. Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients.
Abdulqadhr G; Molin D; Aström G; Suurküla M; Johansson L; Hagberg H; Ahlström H
Acta Radiol; 2011 Mar; 52(2):173-80. PubMed ID: 21498346
[TBL] [Abstract][Full Text] [Related]
24. Comparison of whole-body DW-MRI with 2-[
Baratto L; Nyalakonda R; Theruvath AJ; Sarrami AH; Hawk KE; Rashidi A; Shen S; States L; Aboian M; Jeng M; Daldrup-Link HE
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1689-1698. PubMed ID: 36717409
[TBL] [Abstract][Full Text] [Related]
25. Whole-body diffusion-weighted magnetic resonance imaging versus FDG-PET/CT for initial lymphoma staging: systematic review on diagnostic test accuracy studies.
Regacini R; Puchnick A; Shigueoka DC; Iared W; Lederman HM
Sao Paulo Med J; 2015; 133(2):141-50. PubMed ID: 25789779
[TBL] [Abstract][Full Text] [Related]
26. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
[TBL] [Abstract][Full Text] [Related]
27. Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast.
Catalano OA; Daye D; Signore A; Iannace C; Vangel M; Luongo A; Catalano M; Filomena M; Mansi L; Soricelli A; Salvatore M; Fuin N; Catana C; Mahmood U; Rosen BR
Int J Oncol; 2017 Jul; 51(1):281-288. PubMed ID: 28535000
[TBL] [Abstract][Full Text] [Related]
28. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas.
Albano D; Patti C; La Grutta L; Agnello F; Grassedonio E; Mulè A; Cannizzaro G; Ficola U; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2016 Feb; 85(2):313-8. PubMed ID: 26781135
[TBL] [Abstract][Full Text] [Related]
29.
Hassan A; Siddique M; Bashir H; Riaz S; Wali R; Mahreen A; Nawaz MK
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1198-1206. PubMed ID: 28229191
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma.
Mistry V; Scott JR; Wang TY; Mollee P; Miles KA; Law WP; Hapgood G
Cancer Imaging; 2023 Jan; 23(1):11. PubMed ID: 36694244
[TBL] [Abstract][Full Text] [Related]
31. Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging.
Johnston EW; Latifoltojar A; Sidhu HS; Ramachandran N; Sokolska M; Bainbridge A; Moore C; Ahmed HU; Punwani S
Eur Radiol; 2019 Jun; 29(6):3159-3169. PubMed ID: 30519933
[TBL] [Abstract][Full Text] [Related]
32. Optimization of whole-body 2-[
Burns R; Mulé S; Blanc-Durand P; Tofighi M; Belhadj K; Zerbib P; Le Bras F; Baranes L; Haioun C; Itti E; Luciani A
Eur Radiol; 2022 May; 32(5):3085-3096. PubMed ID: 34842956
[TBL] [Abstract][Full Text] [Related]
33. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L
Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042
[TBL] [Abstract][Full Text] [Related]
34. Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of Outcome.
De Paepe KN; Van Keerberghen CA; Agazzi GM; De Keyzer F; Gheysens O; Bechter O; Wolter P; Dierickx D; Janssens A; Verhoef G; Oyen R; Koole M; Vandecaveye V
Radiol Imaging Cancer; 2021 Mar; 3(2):e200061. PubMed ID: 33817648
[TBL] [Abstract][Full Text] [Related]
35. Correlation of mean apparent diffusion coefficient (ADC) and maximal standard uptake value (SUVmax) evaluated by diffusion-weighted MRI and 18F-FDG-PET/CT in children with Hodgkin lymphoma: a feasibility study.
Rosbach N; Fischer S; Koch V; Vogl TJ; Bochennek K; Lehrnbecher T; Mahmoudi S; Grünewald L; Grünwald F; Bernatz S
Radiol Oncol; 2023 Jun; 57(2):150-157. PubMed ID: 37341195
[TBL] [Abstract][Full Text] [Related]
36. Whole-body MRI versus
Wang D; Huo Y; Chen S; Wang H; Ding Y; Zhu X; Ma C
Onco Targets Ther; 2018; 11():3597-3608. PubMed ID: 29950864
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic value of WB-DWI versus
Zhang B; Zhang L; Bian B; Lin F; Zhu Z; Wang J
Indian J Cancer; 2023; 60(3):303-309. PubMed ID: 37787189
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic Value of Whole-Body DWI With Background Body Suppression Plus Calculation of Apparent Diffusion Coefficient at 3 T Versus
Sun W; Li M; Gu Y; Sun Z; Qiu Z; Zhou Y
AJR Am J Roentgenol; 2020 Feb; 214(2):446-454. PubMed ID: 31799866
[No Abstract] [Full Text] [Related]
39.
Verhagen MV; Menezes LJ; Neriman D; Watson TA; Punwani S; Taylor SA; Shankar A; Daw S; Humphries PD
J Nucl Med; 2021 Nov; 62(11):1524-1530. PubMed ID: 33608429
[TBL] [Abstract][Full Text] [Related]
40. Whole-body-MR imaging including DWIBS in the work-up of patients with head and neck squamous cell carcinoma: a feasibility study.
Noij DP; Boerhout EJ; Pieters-van den Bos IC; Comans EF; Oprea-Lager D; Reinhard R; Hoekstra OS; de Bree R; de Graaf P; Castelijns JA
Eur J Radiol; 2014 Jul; 83(7):1144-1151. PubMed ID: 24768188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
